PGP and cancer: As the result, some well-known TKIs such as osimertinib (Hsiao et al., 2016) and midostaurin (Hsiao et al., 2019), were identified as drug candidates for resensitizing P-gp-overexpressing cancer cells to chemotherapeutic agents (Wu and Fu, 2018).